



LDW

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	<b>10/720,790</b>
	Filing Date	<b>November 21, 2003</b>
	First Named Inventor	<b>David William Banner et al.</b>
	Art Unit	<b>1626</b>
	Examiner Name	<b>Andrew B. Freistein</b>
Total Number of Pages in This Submission	Attorney Docket Number	<b>21500</b>

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	<b>David E. Wildman</b>
Signature	
Date	<b>January 24, 2006</b>

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	<b>David E. Wildman</b>
Signature	
Date	<b>January 24, 2006</b>

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Confirmation No. 5703

David William Banner et al.

Group: 1626

Application No. 10/720,790, filed November 21, 2003  
(Case Docket No. 21500)

Examiner: Andrew B. Freistein

For: **NOVEL MANDELIC ACID DERIVATIVES**

**RESPONSE TO RESRICTION REQUIREMENT**

Nutley, New Jersey 07110  
January 24, 2006

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response the Restriction Requirement mailed December 28, 2005, the Examiner required restriction between the following allegedly independent and distinct groups of claims:

Claim Group I: claims 1 to 61 and 65, said to be drawn to compounds and compositions;

Claim Group II: claims 62 and 63, said to be drawn to processes for synthesizing the compounds of claims 1 to 61;

Claim Group III, claim 64, said to be drawn to an intermediate compound; and

Claim Group IV, claims 66 and 67, said to be drawn to methods for using Group I compounds.

In response, applicants elect claim group I, claims 1 to 61 and 65, with traverse, for further prosecution in this application. Applicants further elect the species (RS)-2-[4-(6-Amino-pyridin-3-yl)-2,6-difluoro-phenyl]-N-(4-carbamimidoyl-2-carbamoylmethoxy-benzyl)-2-ethoxy-acetamide hydrochloride acetic acid, i.e., the compound exemplified in Example 334.3, for further prosecution in this application.

This is the compound represented by formula (I) of claim 1 when R1 and R2 are hydrogen, R3 is carbamoylmethoxy, R4 is hydrogen, R5 is ethyl, R6 is hydrogen, R7 is fluorine, R8 is hydrogen, R9 is 6-amino-pyridin-3-yl, R10 is hydrogen, Y is C, and R11 is fluorine, in the form of the hydrochloride acetic acid salt. Claims 1 to 6, 9 to 20 and 60 read upon the elected species.

Applicants respectfully request that should no prior art be found which anticipates or renders obvious the elected subject matter, search of the claims be continued pursuant to the procedure set forth in MPEP 803.02. Further, applicants request rejoinder of the process claims pursuant to MPEP 821.04.


Applicants traverse on the grounds that the claims are directed to the same inventive concept, i.e., the recited compounds, compositions containing them, and methods for making and using them. The compounds are central to all of these aspects of the invention, and a search for the compounds would also reveal any art directed to how to make and use them. Thus, searching all of the claims would impose no undue burden on the Examiner.

Serial No. 10/720,790  
Filed: November 21, 2003

No fees are believed due. However, the Director is hereby authorized to charge any deficit, or credit any overpayment, to Deposit Account No. 08-2525.

The foregoing election and remarks are fully responsive to the Restriction Requirement issued December 28, 2005. Early and favorable consideration is earnestly solicited.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'David E. Wildman', written over a horizontal line.

Attorney for Applicant(s)

David E. Wildman

(Reg. No. 40226)

340 Kingsland Street

Nutley, NJ 07110

Telephone (973) 235-6385

Telefax: (973) 235-2363

217548